Boehringer Ingelheim has been recognized as one of the 16 Top Employers Worldwide by …
Tag:
Boehringer Ingelheim
-
-
Lifestyle & Health
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart …
-
Pharmaceuticalslider
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Sixty million people across the Middle East may be at risk of developing respiratory …
-
Lifestyle & Health
Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19
Boehringer Ingelheim‘s Global Support Program aiming at bringing more financial relief to the countries …
-
Sharp increase in net sales to nearly 18.1 billion euros (+15.7 per cent …
-
Boehringer Ingelheim releases breakthrough findings on COPD in new study published in the Lancet …
-
Other
Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases
Beirut, Lebanon – 3 July 2017- Boehringer Ingelheim, one of the world’s leading pharmaceutical …
-
Business
Boehringer Ingelheim Middle East and North Africa (MENA) achieved a sales growth of 16% in 2016
Net sales rise to some 15.9 billion euros (currency-adjusted: +7.3 per cent; in euro …
-
Boehringer Ingelheim Middle East and North Africa Region achieved a sales growth of 26% …
Older Posts